Cell Biosciences, Inc. announced the issuance of Patent No. 7,846,676 for “Methods and Devices for Analyte Detection” by the United States Patent and Trademark Office.

The patent represents a key element of intellectual property related to NanoPro assay technology. It is one of several within a family directed towards the detection of specific proteins in complex biological samples. NanoPro assay technology is used by premier researchers in the fields of cancer research, stem cell biology, diabetes and drug development to characterize proteins in extremely small and precious samples, enabling accelerated development of new therapeutics and identification of new prognostic and diagnostic disease biomarkers.

“The NanoPro platform represents a transformational approach to protein characterization,” commented Bob Gavin, vice president of Product Development at Cell Biosciences. “The platform’s ability to study proteins in extremely small samples has led to its adoption by leading research institutions and drug development companies worldwide. We look forward to continuing the delivery of innovative products based on this technology.”

Cell Biosciences, Inc., is headquartered in Santa Clara, California, develops instrumentation systems, software and assay products that drive discoveries in fields ranging from fundamental protein research to biomarker discovery and personalized medicine. With an installed base of over 10,000 systems, our customers include leading research institutions and pharmaceutical/biotechnology companies worldwide.